FDA OKs higher dose of Merck's HIV drug

The Food and Drug Administration on Tuesday approved a new dose of Merck's HIV drug Isentress.

Patients may now take a 1,200 milligram once-daily dose of Isentress in combination with other antiretroviral treatments. Merck already offers the drug in a 400 milligram twice-daily formulation.

Merck expects the new version of the drug to hit pharmacy shelves within a month.

More articles on supply chain:

Amgen sues FDA over drug exclusivity rights: 5 things to know
Appellate court: Fairvew Health's medical device telemarketing does not violate robocall rules
Drug execs anticipate Trump's drug pricing plans: 4 things to know

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars